(Reuters) – Abbott Laboratories (NYSE:) slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.
The company now expects a full-year profit of $4.64 to $4.70 per share, with the midpoint a tad higher than that of its earlier forecast of $4.61 to $4.71 per share.
On an adjusted basis, the company’s quarterly profit of $1.21 per share beat analysts’ average expectations of $1.20 per share, according to estimates compiled by LSEG.
